MaxCyte (MXCT) is maintaining excellent commercial momentum across its cell therapy business, which led to 21% year-on-year top-line growth to US$26.2mln in fiscal (FY) 2020. This included three new strategic licences with high profile cell therapy developers, a fourth signed post period, a rise in

29 Apr 2021
MaxCyte: 2020 revenues up 21% as industry enters new growth era

Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
MaxCyte: 2020 revenues up 21% as industry enters new growth era
MaxCyte (MXCT) is maintaining excellent commercial momentum across its cell therapy business, which led to 21% year-on-year top-line growth to US$26.2mln in fiscal (FY) 2020. This included three new strategic licences with high profile cell therapy developers, a fourth signed post period, a rise in